CAMBRIDGE, Mass., Feb. 9 /PRNewswire/ -- Peptimmune Inc. announced
today that Thomas P. Mathers, President and Chief Executive Officer, will
speak at the BIO CEO & Investor Conference on Tuesday February 13th at 12pm
EST in the Carnegie Suite. The conference will be held at New York's
Waldorf-Astoria Hotel. Mr. Mathers' presentation will provide an overview
of the progress of the Company.
About Peptimmune:
Peptimmune, Inc. is a privately held clinical stage biotechnology
company developing a pipeline of peptide based therapeutics for the
treatment of chronic inflammatory diseases. The company is developing
second generation therapeutics that are expected to result in safer and
more effective therapies for multiple sclerosis, pemphigus vulgaris,
rheumatoid arthritis and obesity. Founded by a team of world class
scientists and led by an experienced management team, Peptimmune's mission
is to reduce the burden these diseases place on the individuals, their
families and the healthcare system. For information, access our website at
http://www.peptimmune.com.
SOURCE Peptimmune, Inc.
 back to top
Related links:
http://www.peptimmune.com/
CONTACT:
Dustan Bonnin, Business Development, of
Peptimmune, Inc., +1-617-715-8043, or
dustan.bonnin@peptimmune.com
|
